Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Biogen Idec
(NQ:
BIIB
)
201.99
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 24, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Biogen Idec
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
37
38
Next >
The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree
June 02, 2023
Big Pharma is facing a patent cliff that could siphon off billions in revenue.
Via
Investor's Business Daily
Biogen Hits Buy Zone On A Fresh Win In Alzheimer's Disease; Eli Lilly, Eisai Shares Jump
June 01, 2023
The news also benefits Biogen's partner Eisai and rival Eli Lilly.
Via
Investor's Business Daily
How Biohaven Is Coming 'Out Of Stealth Mode' — And Bullishly Extending A 4-Day Run
June 01, 2023
Shares surged into and out of the company's R&D Day, which included a surprise.
Via
Investor's Business Daily
Rotation Out Of Healthcare And Biotech Stocks: Age Of Disruption?
May 30, 2023
A steady rotation out of biotech and healthcare stocks into the Nasdaq-100 large-cap tech stocks can be unnerving for portfolio managers.
Via
Talk Markets
Biogen Unusual Options Activity For May 26
May 26, 2023
Via
Benzinga
Analyst Ratings for Biogen
May 23, 2023
Via
Benzinga
If You Invested $1000 In This Stock 15 Years Ago, You Would Have $5,500 Today
May 19, 2023
Via
Benzinga
(BIIB) - Analyzing Biogen's Short Interest
May 10, 2023
Via
Benzinga
3 Biotech Stocks That Are Revolutionizing Healthcare in 2023
May 19, 2023
Here are three of the best biotech stocks to buy; each is on the verge of significant breakthroughs that may send the price higher.
Via
InvestorPlace
1 Major Advantage Biogen May Have Over Pharma Giant Eli Lilly in a Multibillion-Dollar Market
May 19, 2023
Analysts are bullish on Biogen's Alzheimer's drug, Leqembi, projecting it may generate over $10 billion in sales at its peak.
Via
The Motley Fool
Eli Lilly's Alzheimer's Drug Is Just Version 1.0. But It's Still On Track For Blockbuster Status, Analyst Says.
May 15, 2023
An analyst says Lilly's donanemab could become a blockbuster in its second year on the market.
Via
Investor's Business Daily
These 2 Pharma Stocks Might Face Off Soon -- but They Could Both Win
May 14, 2023
There's no rule that says a market must have only one winner.
Via
The Motley Fool
3 Reasons to Buy Biogen Stock (and 1 to Sell)
May 12, 2023
The stock has been rallying but how it performs from here will likely depend on the fate of its Alzheimer's treatment, Leqembi.
Via
The Motley Fool
Here’s What Eli Lilly’s Latest Clinical Win Means For Investors
May 12, 2023
The biotech's prospects continue to get brighter.
Via
The Motley Fool
P/E Ratio Insights for Biogen
May 08, 2023
Via
Benzinga
Elliott Wave Technical Analysis: Biogen Inc. - Monday, May 8
May 08, 2023
Looking for longs on the way up into wave (3), as long as every downside pullback is a three wave move.
Via
Talk Markets
Biogen Unusual Options Activity
May 05, 2023
Via
Benzinga
Here's Why Eli Lilly's Alzheimer's Drug Could Be the Real Deal
May 11, 2023
Eli Lilly stock may look expensive, but there's still plenty of value here for long-term investors.
Via
The Motley Fool
Royalty Pharma Reaffirms FY23 Guidance Post Mixed Q1 Performance
May 09, 2023
Via
Benzinga
Analysts Say Eli Lilly's Donanemab In Alzheimer's Is Encouraging, Outline Potential Implications For Biogen
May 04, 2023
Wednesday, Eli Lilly And Co (NYSE: LLY) announced positive results of the TRAILBLAZER-ALZ 2 Phase 3 study of
Via
Benzinga
$1000 Invested In Biogen 15 Years Ago Would Be Worth This Much Today
May 03, 2023
Via
Benzinga
Why Eli Lilly Stock Is Bolting Higher Today
May 03, 2023
Lilly's Alzheimer's disease candidate might be a best-in-class option for patients.
Via
The Motley Fool
Biogen Unusual Options Activity For May 03
May 03, 2023
Via
Benzinga
Looking At Biogen's Recent Unusual Options Activity
April 28, 2023
Via
Benzinga
Another Sucess In Alzheimer’s Disease
May 03, 2023
Eli Lily reported a successful phase III trial of donanemab in Alzheimer’s Disease. How does it differentiate from lecanemab and what does it mean for beta-amyloid treatments?
Via
Talk Markets
Eli Lilly Surges After Alzheimer's Treatment Succeeds; Biogen Also Rises
May 03, 2023
Eli Lilly is focusing on proteins associated with Alzheimer's disease.
Via
Investor's Business Daily
Microsoft, Snap And 2 Other Stocks Insiders Are Selling
May 03, 2023
The S&P 500 closed lower more than 1% on Tuesday. Investors, meanwhile, focused on some notable insider trades.
Via
Benzinga
Biotech Is Back With Guggenheim Upgrade: What You Need To Know
May 01, 2023
Guggenheim Partners upgraded shares of Biogen Inc (NASDAQ: BIIB) to Buy, citing the company's potential for growth driven by its Alzheimer's disease (AD) and major depressive disorder (MDD)...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 1, 2023
May 01, 2023
Via
Benzinga
Despite Its Falling 92%, Cathie Wood Is Buying More of This Growth Stock
May 01, 2023
Wood is betting that Ginkgo Bioworks' biofoundry can scale up enough to become profitable.
Via
The Motley Fool
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
37
38
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.